- Home
- LOAN vs CUE Comparison
LOAN vs CUE Comparison
Compare LOAN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | CUE |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.9M | 27.1M |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LOAN | CUE |
|---|---|---|
| Price | $4.44 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 20.3K | ★ 343.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | 2.08 | ★ 35.14 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $9,688,641.00 | $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $25.00 |
| P/E Ratio | $12.69 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $4.24 | $0.23 |
| 52 Week High | $6.05 | $1.12 |
Technical Indicators
Market Signals| Indicator | LOAN | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 51.95 |
| Support Level | $4.29 | $0.26 |
| Resistance Level | $4.59 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 76.45 | 65.48 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.